Australian medical device company Signostics Limited today announced the appointment of Kevin Goodwin as the company’s new Chief Executive Officer.
Mr Goodwin, who is based in Seattle, has 28 years’ executive experience in the ultrasound industry, with 17 years as the CEO and founder of point-of-care innovator and multinational, Sonosite Inc.
As CEO of Sonosite, Mr Goodwin led the company from its pre-revenue spin off as a US NASDAQ-listed company from April 1998. The company went on to be the category creator and leader in the point-of-care ultrasound market. Sonosite ultimately reached revenues of $300 million under Mr Goodwin’s guidance.
Mr Goodwin’s tenure at Sonosite was credited with many notable achievements, including new market creation, phenomenal long-term sales growth, and the development of a highly innovative philosophy and reputation lauded by customers around the world. Sonosite was acquired by FujiFilm in an all cash transaction in 2012 for just under US$1 billion.
Chairman of Signostics Limited David Keogh said the appointment of Mr Goodwin was a giant leap forward for Signostics and created the chance to become a leading player in cutting-edge healthcare delivery in a rapidly developing sector.
“Kevin was instrumental in creating a new market space in the ultrasound industry and his experience will be critical in building new opportunities for Signostics and customers,” Mr Keogh said.
“The board, management team and Mr Goodwin all share the same view that Signostics can be a platform for next generation innovation in medical ultrasound, offering significant improvements to healthcare delivery.”
Mr Goodwin said he was energized by the opportunity to join Signostics.
“I’ve been immersing myself in new possibilities for medical ultrasound for nearly 20 years and Signostics is the perfect place to be right now. There are so many opportunities to move ultrasound forward through innovation, and this has always been my passion.
“Signostics offers the perfect platform for new “breakout innovations” which will benefit medicine around the world.”
Mr Goodwin takes up his appointment from 1 April, 2015.